Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
about
Irreversible electroporation and the pancreas: What we know and where we are going?A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancerSequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Intravenous ω-3 Fatty Acids Plus Gemcitabine.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple OpponentsPancreatic cancer: pathobiology, treatment options, and drug delivery.Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapyQuality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Systemic therapy for metastatic pancreatic adenocarcinoma.Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinomaAdvanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCommunication and palliative care in a 64-year-old man with pancreatic adenocarcinoma.Metastatic pancreatic cancer: are we making progress in treatment?Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma.Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer.Optimum chemotherapy in the management of metastatic pancreatic cancerManagement of advanced pancreatic cancer.Pancreatic cancer: diagnosis and treatments.Patient-reported outcomes as end points and outcome indicators in solid tumours.Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer.Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study.Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice
P2860
Q26795522-F5FB97D5-BA87-42F7-9FEE-D008C6CD1878Q33398693-5939ADDC-7DE4-4EC1-8FB8-802B51979B61Q33400095-21F5D3DE-36A0-4A99-BFFF-3FC3FC2DB3FEQ33403498-2BBDB1AE-04BB-4EB4-B04A-1D2854EBC3C3Q33424793-9042FF93-34F5-4A27-83A9-C4D601661CC3Q33440500-63BA0F3C-BB21-4D9B-99D6-A141DF5F48E3Q33632330-68E3FA28-96EB-47DA-BAFD-685346D5BBDDQ33704284-219A86E6-E632-422F-B769-C6C6CFCCD557Q33749460-5E21AA64-AC7A-4CF7-B81E-F6CE95DE07AAQ34049255-2325A7FB-87E7-4325-BA35-B8A3A3F4D94AQ34344188-467316E5-AA8A-4FA4-BE9D-952FE53334A3Q34404088-9F606AE7-C5D7-45EB-BA46-B93107302E66Q34818494-2BB46B01-8F15-4CEC-81BE-23498FA7835EQ35076238-0243587F-1F7E-4F2F-87E5-B8364BB32E91Q35076334-6440B458-A960-4735-BC0E-8D105C94B6B8Q35136815-BAEF15F6-0104-491B-AC46-58C9D7698AA2Q35641643-00079F50-CC71-4A41-9E7F-7F30BA5659A7Q35674606-8633801D-69F2-4978-888C-58B7F921E2D8Q35776091-0A5DDA80-8289-4409-8E3E-6B552C4F2EB8Q36035888-E9331B74-3BA2-4F0C-851B-9C7DFBCC269FQ36206909-1FBAAEFA-5461-4D2F-8202-5CEA8903D9F7Q36469038-1E7E1431-C773-4C0D-95BD-2D16C177061EQ36574645-F4D06550-A829-43BA-B488-474C137B06F9Q36654714-68427172-37FF-4C58-9EC4-F962C2E0BD7FQ37614142-FDA53483-81B7-4E50-845E-B739EFBCCA9BQ37617976-935DD902-E46B-4AE9-A56C-50F6AE797FD5Q37960190-C27E408F-D65F-4148-86B0-437A595CB9ECQ38354856-85A3B421-16A6-49A9-94FC-E5C57FA298D0Q38371340-64E9B3AF-4580-4893-AC39-530C1A1FFA26Q38379130-A70BB72C-1414-4F53-A100-7185E736C237Q38645930-0A99F548-BA8A-4B82-9FE3-A28BA6333E2BQ38689014-C336318A-D9F4-48ED-904B-F0213CEDCA55Q39491840-B3B21AB8-3CAF-493B-9ABA-6249355CB3C2Q42607439-B891E0FE-3054-4993-9988-0DEDF6C64F6FQ55152175-F7F99F40-02AB-4560-A557-5F8FED0D6795Q57664242-80CF8885-C8E7-49EE-BA83-7C46069D146D
P2860
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Clinical benefit and quality o ...... -SAKK 44/00-CECOG/PAN.1.3.001.
@en
Clinical benefit and quality o ...... -SAKK 44/00-CECOG/PAN.1.3.001.
@nl
type
label
Clinical benefit and quality o ...... -SAKK 44/00-CECOG/PAN.1.3.001.
@en
Clinical benefit and quality o ...... -SAKK 44/00-CECOG/PAN.1.3.001.
@nl
prefLabel
Clinical benefit and quality o ...... -SAKK 44/00-CECOG/PAN.1.3.001.
@en
Clinical benefit and quality o ...... -SAKK 44/00-CECOG/PAN.1.3.001.
@nl
P2093
P356
P1476
Clinical benefit and quality o ...... -SAKK 44/00-CECOG/PAN.1.3.001.
@en
P2093
Arie Figer
Bernhard C Pestalozzi
Central European Cooperative Oncology Group
Claus-Henning Köhne
Daniel Dietrich
Daniela Gerber
Dieter Koeberle
Emilio Bajetta
Gabriela V Kornek
Jean Bauer
P304
P356
10.1200/JCO.2007.15.6240
P407
P577
2008-08-01T00:00:00Z